il-6/gp130

Bazedoxifene acetate (WAY-TES 424) is a novel selective estrogen receptor modulator (SERM).

Bazedoxifene hydrochloride (TSE 424 hydrochloride) is an orally active, selective, and potent estrogen receptor modulator (SERM) that crosses the blood-brain barrier and is an inhibitor of IL-6/GP130 protein interactions with high affinity for ERα and ERβ. It has a high affinity for ERα and ERβ and can be used to study postmenopausal osteoporosis and vasodilator-related diseases.

LMT-28 is an inhibitor of IL-6 and selectively inhibits IL-6-induced phosphorylation of gp130, STAT3, and JAK2.

Olamkicept (FE-301) is a soluble gp130-Fc-fusion protein that selectively inhibits interleukin 6 (IL-6) trans-signaling by binding to the soluble IL-6 receptor/IL-6 complex.

Bazedoxifene is a non-steroidal, orally active selective estrogen receptor modulator that exhibits activity against ERα and ERβ with IC50 values of 26 nM and 99 nM, respectively. Bazedoxifene also inhibits IL-6/GP130 protein interactions. Bazedoxifene is utilized in research on postmenopausal osteoporosis and pancreatic cancer, serving as a dual-purpose compound for hormonal and cytokine pathway investigations.